Prion diseases are serious, not curable neurodegenerative disorders caused by the accumulation of the misfolded protein PrPScthat represents the pathological variant of the normally folded cellular protein PrPC. Molecules that bind the cellular isoform PrPCpreventing its misfolding, could arrest the progression of pathological conditions related to the abnormal PrP protein. In this context, by combining 3D-QSAR model, derived from pharmacophore-based alignment, with molecular docking procedures and physico-chemical properties prediction we have developed a virtual screening protocol to find novel chemicals able to prevent PrPCmisfolding. We identified different hits characterized by low toxicity and able to inhibit PrPScaccumulation in vitro in prion-infected neuroblastoma cell lines (ScN2a). In this assay, the pyrroloquinoxaline hydrazone 96 showed the higest potency with an IC50value of 1.6 μM. Pyrroloquinoxaline 96 was demonstrated also to bind PrPScaggregates in infected ScN2a cells with a fluorescence pattern comparable to that found for Thioflavin-T. In consideration of its satisfactory physico-chemical properties, including predicted blood brain barrier permeability, 96 could represent an interesting prototypic hit for the development of diagnostic and therapeutic probes for prion diseases.

Identification of novel fluorescent probes preventing PrPSc replication in prion diseases / Zaccagnini, Ludovica; Brogi, Simone; Brindisi, Margherita; Gemma, Sandra; Chemi, Giulia; Legname, Giuseppe; Campiani, Giuseppe; Butini, Stefania. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 127(2017), pp. 859-873. [10.1016/j.ejmech.2016.10.064]

Identification of novel fluorescent probes preventing PrPSc replication in prion diseases

Zaccagnini, Ludovica;Legname, Giuseppe
;
2017

Abstract

Prion diseases are serious, not curable neurodegenerative disorders caused by the accumulation of the misfolded protein PrPScthat represents the pathological variant of the normally folded cellular protein PrPC. Molecules that bind the cellular isoform PrPCpreventing its misfolding, could arrest the progression of pathological conditions related to the abnormal PrP protein. In this context, by combining 3D-QSAR model, derived from pharmacophore-based alignment, with molecular docking procedures and physico-chemical properties prediction we have developed a virtual screening protocol to find novel chemicals able to prevent PrPCmisfolding. We identified different hits characterized by low toxicity and able to inhibit PrPScaccumulation in vitro in prion-infected neuroblastoma cell lines (ScN2a). In this assay, the pyrroloquinoxaline hydrazone 96 showed the higest potency with an IC50value of 1.6 μM. Pyrroloquinoxaline 96 was demonstrated also to bind PrPScaggregates in infected ScN2a cells with a fluorescence pattern comparable to that found for Thioflavin-T. In consideration of its satisfactory physico-chemical properties, including predicted blood brain barrier permeability, 96 could represent an interesting prototypic hit for the development of diagnostic and therapeutic probes for prion diseases.
127
859
873
http://www.journals.elsevier.com/european-journal-of-medicinal-chemistry/
Zaccagnini, Ludovica; Brogi, Simone; Brindisi, Margherita; Gemma, Sandra; Chemi, Giulia; Legname, Giuseppe; Campiani, Giuseppe; Butini, Stefania
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11767/68122
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 34
social impact